Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan vs TPC in Endometrial Cancer
NCT06486441Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2024
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of sacituzumab govitecan in endometrial cancer (EC), sponsored by Gilead Sciences. Started Aug 2024; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06486441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06486441.